Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shuxin Luan, Hongquan Wan, Shijun Wang, He Li & Baogang Zhang. (2017) Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatric Disease and Treatment 13, pages 609-620.
Read now
Read now
Giovanni Martinotti, Gianna Sepede, Maria Signorelli, Eugenio Aguglia & Massimo Di Giannantonio. (2013) Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. Expert Opinion on Pharmacotherapy 14:8, pages 1065-1075.
Read now
Read now
Eduard Vieta & Francesc Colom. (2011) Therapeutic options in treatment-resistant depression. Annals of Medicine 43:7, pages 512-530.
Read now
Read now
Susan L McElroy, Anna Guerdjikova, Nicole Mori & Paul E Keck Jr. (2010) Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opinion on Investigational Drugs 19:12, pages 1527-1544.
Read now
Read now
William V Bobo & Richard C Shelton. (2010) Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression. Expert Review of Neurotherapeutics 10:5, pages 651-670.
Read now
Read now
Tom Bschor. (2010) Therapy-resistant depression. Expert Review of Neurotherapeutics 10:1, pages 77-86.
Read now
Read now
Articles from other publishers (7)
Khulekani Mncube, Marisa Möller & Brian H. Harvey. (2021) Post-weaning Social Isolated Flinders Sensitive Line Rats Display Bio-Behavioural Manifestations Resistant to Fluoxetine: A Model of Treatment-Resistant Depression. Frontiers in Psychiatry 12.
Crossref
Crossref
M. Oppa, I. Ondrejka, D. Cesnekova, I. Tonhajzerova & G. Nosalova. (2017) Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results. European Pharmaceutical Journal 64:1, pages 13-16.
Crossref
Crossref
Chun-Yuan Lin, Yu-Hsin Wu, Hong-Song Wang, Ping-Kun Chen, Yuan-Fu Lin & I-Chia Chien. (2016) RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY. Depression and Anxiety 33:5, pages 435-443.
Crossref
Crossref
Janusz K. Rybakowski. (2012) Bipolarity and inadequate response to antidepressant drugs: Clinical and psychopharmacological perspective. Journal of Affective Disorders 136:1-2, pages e13-e19.
Crossref
Crossref
Zofia Rogóż & Grażyna Skuza. (2011) Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacological Reports 63:6, pages 1547-1552.
Crossref
Crossref
Asunción Romero, Hugo F. Miranda & Margarita M. Puig. (2010) Analysis of the opioid–opioid combinations according to the nociceptive stimulus in mice. Pharmacological Research 61:6, pages 511-518.
Crossref
Crossref
William V. BoboRichard A. EpsteinJr.Jr. & Richard C. Shelton. (2010) Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1945.
Crossref
Crossref